Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study
Identifieur interne : 000275 ( Main/Curation ); précédent : 000274; suivant : 000276Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study
Auteurs : Fabrizio Stocchi [Italie] ; Olivier Rascol [France] ; Karl Kieburtz [États-Unis] ; Werner Poewe [Autriche] ; Joseph Jankovic [États-Unis] ; Eduardo Tolosa [Espagne] ; Paulo Barone [Italie] ; Anthony E. Lang [Canada] ; C. Warren Olanow [Italie, États-Unis]Source :
- Annals of Neurology [ 0364-5134 ] ; 2010-07.
Abstract
Objective: L‐dopa is the most widely used and most effective therapy for Parkinson disease (PD), but chronic treatment is associated with motor complications in the majority of patients. It has been hypothesized that providing more continuous delivery of L‐dopa to the brain would reduce the risk of motor complications, and that this might be accomplished by combining L‐dopa with entacapone, an inhibitor of catechol‐O‐methyltransferase, to extend its elimination half‐life. Methods: We performed a prospective 134‐week double‐blind trial comparing the risk of developing dyskinesia in 747 PD patients randomized to initiate L‐dopa therapy with L‐dopa/carbidopa (LC) or L‐dopa/carbidopa/entacapone (LCE), administered 4× daily at 3.5‐hour intervals. The primary endpoint was time to onset of dyskinesia. Results: In comparison to LC, patients receiving LCE had a shorter time to onset of dyskinesia (hazard ratio, 1.29; p = 0.04) and increased frequency at week 134 (42% vs 32%; p = 0.02). These effects were more pronounced in patients receiving dopamine agonists at baseline. Time to wearing off and motor scores were not significantly different, but trended in favor of LCE treatment. Patients in the LCE group received greater L‐dopa dose equivalents than LC‐treated patients (p < 0.001). Interpretation: Initiating L‐dopa therapy with LCE failed to delay the time of onset or reduce the frequency of dyskinesia compared to LC. In fact, LCE was associated with a shorter time to onset and increased frequency of dyskinesia compared to LC. These results may reflect that the treatment protocol employed did not provide continuous L‐dopa availability and the higher L‐dopa dose equivalents in the LCE group. ANN NEUROL 2010;68:18–27
Url:
DOI: 10.1002/ana.22060
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000324
Links to Exploration step
ISTEX:3606364AF54F057814BFA79EB847BC4E60B58857Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study</title>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Institute of Neurology, IRCCS San Raffaele Pisana, Rome</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U455, Clinical Investigation Center, Faculty of Medicine, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Clinical Investigation Center, Faculty of Medicine, Toulouse</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurosciences, Faculty of Medicine, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurosciences, Faculty of Medicine, Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, University of Rochester, Rochester, NY</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Rochester, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, TX</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Neurology, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation wicri:level="1"><mods:affiliation>Neurology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Neurology Service, Hospital Clinic, University of Barcelona, Barcelona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barone, Paulo" sort="Barone, Paulo" uniqKey="Barone P" first="Paulo" last="Barone">Paulo Barone</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurological Sciences, University of Naples and IDC‐Hermitage, Naples, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurological Sciences, University of Naples and IDC‐Hermitage, Naples</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><mods:affiliation>Division of Neurology, University of Toronto, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Institute of Neurology, IRCCS San Raffaele Pisana, Rome</wicri:regionArea>
</affiliation>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3606364AF54F057814BFA79EB847BC4E60B58857</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/ana.22060</idno>
<idno type="url">https://api.istex.fr/document/3606364AF54F057814BFA79EB847BC4E60B58857/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000324</idno>
<idno type="wicri:Area/Main/Curation">000275</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study</title>
<author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name>
<affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Institute of Neurology, IRCCS San Raffaele Pisana, Rome</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><mods:affiliation>INSERM U455, Clinical Investigation Center, Faculty of Medicine, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U455, Clinical Investigation Center, Faculty of Medicine, Toulouse</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Clinical Pharmacology, Faculty of Medicine, Toulouse</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurosciences, Faculty of Medicine, Toulouse, France</mods:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Neurosciences, Faculty of Medicine, Toulouse</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, University of Rochester, Rochester, NY</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Rochester, Rochester</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department of Neurology, Innsbruck Medical University, Innsbruck</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology, Baylor College of Medicine, Houston, TX</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Neurology, Baylor College of Medicine, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation wicri:level="1"><mods:affiliation>Neurology Service, Hospital Clinic, University of Barcelona, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Neurology Service, Hospital Clinic, University of Barcelona, Barcelona</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Barone, Paulo" sort="Barone, Paulo" uniqKey="Barone P" first="Paulo" last="Barone">Paulo Barone</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurological Sciences, University of Naples and IDC‐Hermitage, Naples, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Neurological Sciences, University of Naples and IDC‐Hermitage, Naples</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="1"><mods:affiliation>Division of Neurology, University of Toronto, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Division of Neurology, University of Toronto, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><mods:affiliation>Institute of Neurology, IRCCS San Raffaele Pisana, Rome, Italy</mods:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Institute of Neurology, IRCCS San Raffaele Pisana, Rome</wicri:regionArea>
</affiliation>
<affiliation wicri:level="2"><mods:affiliation>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, NY</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">État de New York</region>
</placeName>
<wicri:cityArea>Department of Neurology and Neuroscience, Mount Sinai School of Medicine, New York</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Neurology</title>
<title level="j" type="abbrev">Ann Neurol.</title>
<idno type="ISSN">0364-5134</idno>
<idno type="eISSN">1531-8249</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-07">2010-07</date>
<biblScope unit="volume">68</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="18">18</biblScope>
<biblScope unit="page" to="27">27</biblScope>
</imprint>
<idno type="ISSN">0364-5134</idno>
</series>
<idno type="istex">3606364AF54F057814BFA79EB847BC4E60B58857</idno>
<idno type="DOI">10.1002/ana.22060</idno>
<idno type="ArticleID">ANA22060</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: L‐dopa is the most widely used and most effective therapy for Parkinson disease (PD), but chronic treatment is associated with motor complications in the majority of patients. It has been hypothesized that providing more continuous delivery of L‐dopa to the brain would reduce the risk of motor complications, and that this might be accomplished by combining L‐dopa with entacapone, an inhibitor of catechol‐O‐methyltransferase, to extend its elimination half‐life. Methods: We performed a prospective 134‐week double‐blind trial comparing the risk of developing dyskinesia in 747 PD patients randomized to initiate L‐dopa therapy with L‐dopa/carbidopa (LC) or L‐dopa/carbidopa/entacapone (LCE), administered 4× daily at 3.5‐hour intervals. The primary endpoint was time to onset of dyskinesia. Results: In comparison to LC, patients receiving LCE had a shorter time to onset of dyskinesia (hazard ratio, 1.29; p = 0.04) and increased frequency at week 134 (42% vs 32%; p = 0.02). These effects were more pronounced in patients receiving dopamine agonists at baseline. Time to wearing off and motor scores were not significantly different, but trended in favor of LCE treatment. Patients in the LCE group received greater L‐dopa dose equivalents than LC‐treated patients (p < 0.001). Interpretation: Initiating L‐dopa therapy with LCE failed to delay the time of onset or reduce the frequency of dyskinesia compared to LC. In fact, LCE was associated with a shorter time to onset and increased frequency of dyskinesia compared to LC. These results may reflect that the treatment protocol employed did not provide continuous L‐dopa availability and the higher L‐dopa dose equivalents in the LCE group. ANN NEUROL 2010;68:18–27</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000275 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000275 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:3606364AF54F057814BFA79EB847BC4E60B58857 |texte= Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study }}
This area was generated with Dilib version V0.6.23. |